Find Clinical Trial

Efficacy and safety of gliclazide MR (30 to 120 mg per day) associated or not to metformine or to an a-glucosidase inhibitor during the fast of the Ramadan in type 2 diabetic patients. A 5 to 8 months, national, multicentre, open study. Efficacité et tolérance du gliclazide LM (30 à 120 mg/j per os) associé ou non à la metformine ou à un inhibiteur des a-glucosidases pendant le jeûne du Ramadan chez des patients diabétiques de type 2. Etude nationale, multicentrique de 5 à 8 mois de traitement en ouvert.

← Back
Study Phase

Phase 3

Therapeutic Area


IndicationDiabetes - Type II
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device


Active Substance CodeS005702
Protocol CodeCL3-05702-014
EudraCT Code2006-006754-10

Documents and links

Results summary READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.